Clinical Trial Update: Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tadalafil for pulmonary hypertension due to chronic lung disease (COPD) has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Pulmonary Hypertension

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2021-03-09